

Oncology Today with Dr Neil Love: Hodgkin Lymphoma Edition
(Audio Interview)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. What was the median number of cycles of consolidation brentuximab vedotin (BV) administered on the Phase III AETHERA trial, which evaluated this agent as consolidation therapy after autologous stem cell transplant for patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or disease progression?
 - a. 8
 - b. 11
 - c. 16
2. Risk factors to consider when evaluating a patient with HL for use of consolidation BV after transplant include which of the following?
 - a. Prior treatment status
 - b. Presence of Stage IV disease at relapse
 - c. Presence of B symptoms at relapse
 - d. Duration of remission
 - e. Status of response to initial therapy
 - f. All of the above
3. The ongoing US Intergroup Phase III study SWOG-S1826 is evaluating which of the following regimens for patients with newly diagnosed advanced-stage cHL?
 - a. Doxorubicin/vinblastine/dacarbazine (AVD) + BV versus AVD + pembrolizumab
 - b. AVD/bleomycin (ABVD) versus AVD + nivolumab
 - c. ABVD versus AVD + BV
 - d. AVD + BV versus AVD + nivolumab
4. Which of the following outcomes was observed on a study presented by Moskowitz and colleagues at ASH 2019 evaluating pembrolizumab in combination with GVD (gemcitabine/vinorelbine/doxorubicin) for patients with relapsed/refractory cHL?
 - a. High rates of response, including complete responses
 - b. Minimal rates of response